Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar-Apr;32(2):505-10.
doi: 10.12669/pjms.322.8496.

Diabetic Macular Edema

Fatih C Gundogan  1 , Umit Yolcu  2 , Fahrettin Akay  3 , Abdullah Ilhan  4 , Gokhan Ozge  5 , Salih Uzun  6
Affiliations
Review

Diabetic Macular Edema

Fatih C Gundogan et al. Pak J Med Sci. 2016 Mar-Apr.

Abstract

Diabetic macular edema (DME), one the most prevalent causes of visual loss in industrialized countries, may be diagnosed at any stage of diabetic retinopathy. The diagnosis, treatment, and follow up of DME have become straightforward with recent developments in fundus imaging, such as optical coherence tomography. Laser photocoagulation, intravitreal injections, and pars plana vitrectomy surgery are the current treatment modalities; however, the positive effects of currently available intravitreally injected agents are temporary. At this point, further treatment choices are needed for a permanent effect.

Sources of data selection: The articles published between 1985-2015 years on major databases were searched and most appropriate 40 papers were used to write this review article.

Keywords: Bevacizumab; Diabetic macular edema; Fluorescein angiography; Optical coherence tomography; Pars plana vitrectomy; Ranibizumab; Triamcinolone acetonide.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Diabetic macular edema in the right (1a) and left eye (1b) of a patient.
Fig.2
Fig.2
Fundus fluorescein angiography (FFA) (2a) and optical coherence tomography (2b) images of diabetic macular edema. Fluorescein leakage (2a) and cystoid spaces (2b) are seen in FFA and OCT, respectively.
Fig.3
Fig.3
Schematic view of clinically significant macular edema.
Fig.4
Fig.4
Fundoscopic view (4a) and fluorescein angiography (4b) of a diabetic retinopathy patient with vascular leakage in the temporal retina and focal macular edema.
Fig.5
Fig.5
Optical coherence tomography images before the ranibizumab injection (5a, 5b) and after three monthly injections of ranibizumab (5c, 5d).
See this image and copyright information in PMC

References

    1. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859–1868. doi:10.1016/j.ophtha.2008.08.023. - PMC - PubMed
    1. Paulus YM, Gariano RF. Diabetic retinopathy: A growing concern in an aging population. Geriatrics. 2009;64(2):16–20. - PubMed
    1. Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27. doi:10.1186/2045-3701-4-27. - PMC - PubMed
    1. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59(5):1244–1253. doi:10.2337/db09-1216. - PMC - PubMed
    1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1–32. doi:10.1016/j.survophthal.2008.10.001. - PubMed